April 2020 NDA/BLA Inspection Schedule by CFDI for NMPA:
| No. | Acceptance number | Company | Products |
| 1 | CXSS1900005 | Xinjiang Deyuan Bioengineering | Human Immunnglnhlobulin (pH4) for Intravenous Injection |
| 2 | CXSS1700033 | Shanxi Kangbao Biological | Human coagulation factor Ⅷ |
| 3 | CYHS1900202 | Chongqing Huapont Pharm | Aminosalicylate Enteric-CoatedGranules |
| 4 | CXHS1800035 | Yichang Humanwell Pharma | Ramimazolam Besilate for Injection |
| 5 | CXSS1800029 | Heibei Daan Pharma | Human Immunnglnhlobulin (pH4) for Intravenous Injection |
| 6 | Y20190000075 | Chongqing Huapont Kaisheng Pharm | Aminosalicylate |
| 7 | CYSB1800230 | Beijing Kawin Technology | Recombinant Human Interferon α2b Injection |
| 8 | CYSB1800229 | Beijing Kawin Technology | Recombinant Human Interferon α2b Injection |
| 9 | CYSB1800228 | Beijing Kawin Technology | Recombinant Human Interferon α2b Injection |
| 10 | CYSB1800231 | Beijing Kawin Technology | Recombinant Human Interferon α2b Vaginal Effervescent Tablets |
| 11 | CXSS1900029 | Heibei Daan Pharma | Human Prothrombin Complex |
| 12 | CXSS1800007 | China Biologic Products | Human coagulation factor IX |
| 13 | Y20180000992 | Nanjing Chia Tai Tianqing Pharma | Clopidogrel Hydrogen Sulphate |
| 14 | CXSS1800007 | China Biologic Products | Human coagulation factor IX |
| 15 | CYHS1800138 | HEC Pharm | Linagliptin and Metformin Hydrochloride Tablets（Ⅲ） |
| 16 | CXHS1800034 | Yichang Humanwell Pharma | Ramimazolam Besilate |
| 17 | CYHS1800136 | HEC Pharm | Linagliptin and Metformin Hydrochloride Tablets（Ⅰ） |
| 18 | CYHS1800137 | HEC Pharm | Linagliptin and Metformin Hydrochloride Tablets（Ⅱ） |
评论